Please enable JavaScript.

Coggle requires JavaScript to display documents.

Pediaditakis, I. et al. Modeling alpha-synuclein pathology in a human…

- - - - Human Endothelial-SFM (hESFM; Gibco)
      - 1% Human Platelet-Poor Plasma-derived bovine Serum (PDS)
      - 20 ng/mL basic Fibroblast Growth Factor (bFGF)
      - 10 uM all-trans Retinoic Acid (initial 48 hours post-seeding)
      - 1% Penicillin-Streptomycin
      - Continuous microfluidic flow at 30 uL/h
  - - - BrainPhys Imaging Optimized Medium
      - 2% NeuroCult SM1 Neuronal Supplement
      - 1% N2 Supplement-A
      - 20 ng/mL human recombinant BDNF
      - 20 ng/mL human recombinant GDNF
      - 1 ug/mL Laminin
      - 1% Penicillin-Streptomycin
      - Continuous microfluidic flow at 30 uL/h
- - - - DMEM/F-12
      - 20% KnockOut Serum Replacement (KSR)
      - 1% MEM Non-Essential Amino Acids (NEAA)
      - 1 mM L-glutamine
      - 0.1 mM beta-mercaptoethanol
  - - - Human Endothelial-SFM
      - 20 ng/mL bFGF
      - 10 uM Retinoic Acid